Cargando…

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma

BACKGROUND: The emergence of immune checkpoint inhibitors (ICIs) marks the beginning of a new era of immunotherapy for hepatocellular carcinoma (HCC), however, not all patients respond successfully to this treatment. A major challenge for HCC immunotherapy is the development of ways to screen for th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lin, Zhou, Qiaodan, Liu, Junjie, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581472/ https://www.ncbi.nlm.nih.gov/pubmed/34777372 http://dx.doi.org/10.3389/fimmu.2021.759565

Ejemplares similares

Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation
por: Ding, Xiao, et al.
Publicado: (2014)

An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma
por: Mo, Zhuomao, et al.
Publicado: (2020)

Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma
por: Hong, Ting, et al.
Publicado: (2022)

Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma
por: Cai, Jialiang, et al.
Publicado: (2022)

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
por: Giraud, Julie, et al.
Publicado: (2021)

Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma
por: Yu, Hongjun, et al.
Publicado: (2022)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma
por: Shi, Yanlong, et al.
Publicado: (2022)

IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma
por: Liu, Chengdong, et al.
Publicado: (2022)

Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma
por: Liang, Haifeng, et al.
Publicado: (2023)

CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target
por: Jiang, Qianwei, et al.
Publicado: (2023)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma
por: Yu, Xue, et al.
Publicado: (2022)

Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma
por: Lee, Seung Eun, et al.
Publicado: (2016)

Prognostic stratification based on m(5)C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Ping, et al.
Publicado: (2022)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
por: Liu, Zhuoyan, et al.
Publicado: (2021)

Detection of CTNNB1 Hotspot Mutations in Cell-Free DNA from the Urine of Hepatocellular Carcinoma Patients
por: Lin, Selena Y., et al.
Publicado: (2021)

Prognostic significance of CTNNB1 mutation in hepatocellular carcinoma: a systematic review and meta-analysis
por: Lu, Genlin, et al.
Publicado: (2023)

Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm
por: Wang, Tao, et al.
Publicado: (2022)

Development and validation of a CTNNB1‐associated metabolic prognostic model for hepatocellular carcinoma
por: Huo, Junyu, et al.
Publicado: (2020)

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
por: Shen, Jianming, et al.
Publicado: (2022)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Xing, Rui, et al.
Publicado: (2021)

Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
por: Li, Jiarui, et al.
Publicado: (2023)

Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
por: Zhu, Jinfeng, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
por: Wang, Kunpeng, et al.
Publicado: (2021)

CTNNB1 in neurodevelopmental disorders
por: Zhuang, Wenting, et al.
Publicado: (2023)

Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma
por: Sun, Liang, et al.
Publicado: (2023)

Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective
por: Chen, Shuling, et al.
Publicado: (2022)

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody
por: Liu, Chenxi, et al.
Publicado: (2022)

Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma
por: Tang, Yuqin, et al.
Publicado: (2022)

Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma
por: Wang, Yuxin, et al.
Publicado: (2023)

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
por: Tai, David, et al.
Publicado: (2019)

Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience
por: Ogawa, Keita, et al.
Publicado: (2022)

Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma
por: Jiang, Silin, et al.
Publicado: (2023)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration
por: Jiang, Yuchuan, et al.
Publicado: (2021)

Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma
por: Zhao, Ming, et al.
Publicado: (2023)

The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma
por: Su, Jiaming, et al.
Publicado: (2023)

Unveiling efferocytosis-related signatures through the integration of single-cell analysis and machine learning: a predictive framework for prognosis and immunotherapy response in hepatocellular carcinoma
por: Liu, Tao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lbkhns94k97kve1rl7uv441nsu